AI-Driven Computer System Validation for Next-Gen GxP Compliance
DOI:
https://doi.org/10.22399/ijcesen.4368Keywords:
Artificial Intelligence, Computer System Validation, GxP Compliance, Machine Learning, Continuous ValidationAbstract
As the field of artificial intelligence (AI) quickly infiltrates the life sciences and pharmaceutical industry, its disruptive quality in Good x Practice (GxP) compliance is increasingly becoming a plausible development particularly in the area of Computer System Validation (CSV). The traditional validation procedures that are rather inert, paper-based, and manual were not applicable in the world of agile development cycles, SaaS applications, and continuous system improvement. AI-Based CSV offers real-time risk evaluation, dynamic, intelligent automation, which is more efficient, precise, and in line with the regulations. The paper will look at the history of validation practices, the role of AI technologies, machine learning, and natural language processing, and the regulatory framework that is shifting to accommodate such a shift. It further examines these concerns as model explainability, data integrity, cybersecurity, and lifecycle governance, and offers a strategic outlook of AI as an initial tool for ensuring a continual validation. The paper also outlines the importance of AI in the next-generation GxP compliance and ensures data integrity in a more digitised regulatory environment in depth.
References
1. Adrion, W. R., Branstad, M. A., & Cherniavsky, J. C. (1982). Validation, verification, and testing of computer software. ACM Computing Surveys (CSUR), 14(2), 159-192.
2. Black, J., & Murray, A. D. (2019). Regulating AI and machine learning: setting the regulatory agenda. European journal of law and technology, 10(3).
3. Gade, P. K. (2023). AI-Driven Blockchain Solutions for Environmental Data Integrity and Monitoring. NEXG AI Review of America, 4(1), 1-16.
4. Kodumuru, R., Sarkar, S., Parepally, V., & Chandarana, J. (2025). Artificial Intelligence and Internet of Things Integration in Pharmaceutical Manufacturing: A Smart Synergy. Pharmaceutics, 17(3), 290.
5. Ladner, T., Weh, C., Dhillon, A., Giffard, M., & Iacovelli, D. (2025). Data computation platform (DCP): empowering pharma 4.0 innovation through a GxP-compliant and scalable software platform enabling advanced data analytics and real-time process monitoring in regulated environments. Journal of Intelligent Manufacturing, 1-19.
6. Božić, V. (2023). The Role of Artificial Intelligence in Risk Management. Assessment, 3, 4.
7. Ogunwole, O., Onukwulu, E. C., Joel, M. O., Adaga, E. M., & Ibeh, A. I. (2023). Modernising legacy systems: A scalable approach to next-generation data architectures and seamless integration. International Journal of Multidisciplinary Research and Growth Evaluation, 4(1), 901-909.
8. Hartung, T., & Kleinstreuer, N. (2025). Challenges and opportunities for validation of AI-based new approach methods. ALTEX-Alternatives to animal experimentation, 42(1), 3-21.
9. Kasurinen, J., Taipale, O., & Smolander, K. (2010). Software test automation in practice: empirical observations. Advances in Software Engineering, 2010(1), 620836.
10. Pervez, Z., Khattak, A. M., Lee, S., & Lee, Y. K. (2010, May). Dual validation framework for multi-tenant saas architecture. In 2010 5th International Conference on Future Information Technology (pp. 1-5). IEEE.
11. Radziwill, N. M., & Benton, M. C. (2017). Evaluating the quality of chatbots and intelligent conversational agents. arXiv preprint arXiv:1704.04579.
12. Ramchand, S., Shaikh, S., & Alam, I. (2021, August). Role of artificial intelligence in software quality assurance. In Proceedings of SAI Intelligent Systems Conference (pp. 125-136). Cham: Springer International Publishing.
13. Oluoha, O. M., Odeshina, A., Reis, O., Okpeke, F., Attipoe, V., & Orieno, O. H. (2022). A Unified Framework for Risk-Based Access Control and Identity Management in Compliance-Critical Environments.
14. De Silva, D., & Alahakoon, D. (2022). An artificial intelligence life cycle: From conception to production. Patterns, 3(6).
15. Boppiniti, S. T. (2023). Data ethics in ai: Addressing challenges in machine learning and data governance for responsible data science. International Scientific Journal for Research, 5(5), 1-29.
16. Currie, N. (2019). Risk-based approaches to artificial intelligence. Crowe Data Management.
17. Belghachi, M. (2023). A review of explainable artificial intelligence methods, applications, and challenges. Indonesian Journal of Electrical Engineering and Informatics (IJEEI), 11(4), 1007-1024.
18. Saha, K., & Okmen, N. (2025). Artificial Intelligence in Pharmacovigilance: Leadership for Ethical AI Integration and Human-AI Collaboration in the Pharmaceutical Industry.
19. Nair, S. (2025). Explainable AI in GXP Validation: Balancing Automation, Traceability, And Regulatory Trust in The Pharmaceutical Industry. Clinical Medicine And Health Research Journal, 5(05), 1430-1442.
20. Han, H., Shiwakoti, R. K., Jarvis, R., Mordi, C., & Botchie, D. (2023). Accounting and auditing with blockchain technology and artificial Intelligence: A literature review. International Journal of Accounting Information Systems, 48, 100598.
21. Hacker, P. (2021). A legal framework for AI training data, from first principles to the Artificial Intelligence Act. Law, innovation and technology, 13(2), 257-301.
22. Torkzadehmahani, R., Nasirigerdeh, R., Blumenthal, D. B., Kacprowski, T., List, M., Matschinske, J., ... & Baumbach, J. (2022). Privacy-preserving artificial intelligence techniques in biomedicine. Methods of information in medicine, 61(S 01), e12-e27.
23. Saha, S. (2023). Improving Software Development Using AI-Enabled Predictive Analytics. Journal of Artificial Intelligence, Machine Learning & Data Science.
24. Hughes, E. (2015). AI-Driven Cybersecurity System: Benefits and Vulnerabilities. International Journal of Artificial Intelligence and Machine Learning, 6(1).
25. Pedro, F., Veiga, F., & Mascarenhas-Melo, F. (2023). Impact of GAMP 5, data integrity and QbD on quality assurance in the pharmaceutical industry: How obvious is it?. Drug Discovery Today, 28(11), 103759.
26. Gonzalez Santacruz, E., Romero, D., Noguez, J., & Wuest, T. (2025). Integrated quality 4.0 framework for quality improvement based on Six Sigma and machine learning techniques towards zero-defect manufacturing. The TQM Journal, 37(4), 1115-1155.
27. Kumar, P. (2024). AI-Powered Fraud Prevention in Digital Payment Ecosystems: Leveraging Machine Learning for Real-Time Anomaly Detection and Risk Mitigation. Journal of Information Systems Engineering and Management 2024, 9(4) e-ISSN: 2468-4376
28. Pasas-Farmer, S., & Jain, R. (2025). From discovery to delivery: Governance of AI in the pharmaceutical industry. Green Analytical Chemistry, 13, 100268.
29. Samhan, L. F., Alfarra, A. H., Abu-Nasser, B. S., & Abu-Naser, S. S. (2025). Future Directions: Emerging trends and future potential of AI in autonomous systems.
30. Andersen, M. E., McMullen, P. D., Phillips, M. B., Yoon, M., Pendse, S. N., Clewell, H. J., ... & Clewell, R. A. (2019). Developing context-appropriate toxicity testing approaches using new alternative methods (NAMs). ALTEX-Alternatives to animal experimentation, 36(4), 523-534.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 International Journal of Computational and Experimental Science and Engineering
This work is licensed under a Creative Commons Attribution 4.0 International License.
